UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NYSE: CHD S&P 500 Component |
| Industry | Dental, Medical |
| Founded | 1847: as John Dwight and Company 1896: as Church & Dwight, Co. |
| Founder | John Dwight |
| Headquarters | Ewing, New Jersey, U.S. |
|
Key people
|
Matthew T. Farrell, CEO |
| Products | Laundry detergent Baking soda Depilatories Pregnancy tests |
| Revenue | $3.4 billion (2015) |
|
Number of employees
|
4,145 (as of 2015) |
| Divisions | Arm & Hammer, Nair First Response, OxiClean Brillo |
| Website | www |
Church & Dwight Co, Inc. is a major American manufacturer of household products that is based in Ewing, New Jersey. While it manufactures many items, it is best known for its Arm & Hammer line which includes baking soda and a variety of products made with it. Church & Dwight was ranked #652 in the Fortune 500 listing of companies in 2017.
The company was founded in 1846 to unify two companies created by John Dwight of Massachusetts and his brother-in-law, Austin Church of Connecticut. Their partnership had begun in 1846 with the two founders selling sodium bicarbonate (also known as baking soda) that they refined in Dwight's kitchen.
The Arm & Hammer logo, which dates back to the 1860s, is often incorrectly claimed to have originated with tycoon Armand Hammer. Hammer was so often asked about the Church & Dwight brand, however, that he attempted to buy the company. While unsuccessful, Hammer's Occidental Petroleum in 1986 acquired enough stock for him to join the Church & Dwight board of directors.
In 2001 the consumer product line of Carter-Wallace was sold to Church and Dwight and MedPointe bought the diagnostics and drug businesses.
Church and Dwight acquired Orange Glo International, giving them OxiClean and Orange Glo in 2006. Church & Dwight was ranked 723 in the Fortune 500 listing of companies in 2010.
In 2017, MidOcean Partners agreed to sell Waterpik for $1 billion to Church & Dwight. At the time of the sale announcement, it was reported that Water Pik, Inc. had "$265 million of revenue in the fiscal year ended June 30, about 70% of which came from its water flosser products".
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q4 2022 | 2023-02-03 | Future report Set alerts | |
| Q3 2022 | 2022-10-28 | 0.76 | 0.76 |
| Q2 2022 | 2022-07-29 | 0.76 | 0.76 |
| Q1 2022 | 2022-04-28 | 0.83 | 0.83 |
| Q4 2021 | 2022-01-28 | 0.64 | 0.64 |
| Q3 2021 | 2021-10-29 | 0.80 | 0.80 |
| Q2 2021 | 2021-07-30 | 0.76 | 0.76 |
| Q1 2021 | 2021-04-29 | 0.83 | 0.83 |
| Q4 2020 | 2021-01-29 | 0.53 | 0.53 |
| Q3 2020 | 2020-10-29 | 0.70 | 0.70 |
| 2016-07-11 | Initiated Coverage | Stifel Nicolaus | Hold | |
| 2016-05-22 | Reiterated Rating | Deutsche Bank | Buy | |
| 2016-05-22 | Reiterated Rating | Deutsche Bank AG | Buy | |
| 2016-05-20 | Reiterated Rating | Goldman Sachs | Sell | $81.00 |
| 2016-05-20 | Reiterated Rating | Goldman Sachs Group Inc. | Sell | $81.00 |
| 2016-05-19 | Reiterated Rating | Jefferies Group | Buy | $112.00 |
| 2016-05-09 | Reiterated Rating | Jefferies Group | Buy | $106.00 to $112.00 |
| 2016-04-18 | Downgrade | Bank of America | Neutral to Underperform | $97.00 |
| 2016-04-18 | Downgrade | Bank of America Corp. | Neutral to Underperform | $97.00 |
| 2016-02-04 | Boost Price Target | Societe Generale | Hold | $94.00 to $97.00 |
| 2016-02-03 | Boost Price Target | Jefferies Group | Buy | $93.00 to $97.00 |
| 2016-02-03 | Reiterated Rating | Deutsche Bank | Buy | $89.00 to $94.00 |
| 2016-02-02 | Reiterated Rating | William Blair | Outperform | |
| 2016-01-13 | Downgrade | Goldman Sachs | Neutral to Sell | |
| 2015-11-03 | Lower Price Target | Jefferies Group | Buy | $100.00 to $98.00 |
| 2015-10-13 | Initiated Coverage | Societe Generale | Hold | |
| 2015-08-20 | Lower Price Target | Barclays | Underweight | $83.00 to $81.00 |
| 2015-08-20 | Lower Price Target | Barclays PLC | Underweight | $83.00 to $81.00 |
| 2015-08-06 | Reiterated Rating | Williams Capital | Buy | $97.00 to $98.00 |
| 2015-07-20 | Initiated Coverage | Sterne Agee CRT | Neutral | |
| 2015-06-01 | Reiterated Rating | Jefferies Group | Buy | $97.00 |
| 2015-04-29 | Downgrade | CIBC | Hold | $90.00 |
| 2015-04-29 | Downgrade | Oppenheimer | Outperform to Market Perform | $76.00 to $90.00 |
| 2015-04-29 | Downgrade | Oppenheimer Holdings Inc. | Outperform to Market Perform | $76.00 to $90.00 |
| 2015-04-20 | Downgrade | Goldman Sachs | Buy to Neutral | $89.00 to $88.00 |
| 2015-04-10 | Boost Price Target | Williams Capital | Buy | $81.00 to $97.00 |
| 2015-04-02 | Reiterated Rating | Citigroup Inc. | Hold | $83.00 to $90.00 |
| 2015-02-04 | Set Price Target | BTIG Research | Buy | $95.00 |
| 2015-02-04 | Set Price Target | Credit Suisse | Hold | $82.00 |
| 2015-02-04 | Upgrade | Bank of America | Underperform to Neutral | $75.00 to $85.00 |
| 2015-02-04 | Set Price Target | Credit Suisse Group AG | Hold | $82.00 |
| 2015-01-26 | Boost Price Target | Jefferies Group | Buy | $82.00 to $93.00 |
| 2015-01-21 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $74.00 to $85.00 |
| 2015-01-15 | Reiterated Rating | Deutsche Bank | Buy | $80.00 to $85.00 |
| 2014-12-23 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $74.00 to $85.00 |
| 2014-12-11 | Initiated Coverage | Raymond James | Market Perform | |
| 2014-12-11 | Initiated Coverage | Raymond James Financial Inc. | Market Perform | |
| 2014-11-19 | Initiated Coverage | BTIG Research | Buy | $84.00 |
| 2014-11-11 | Reiterated | Williams Capital Group | Buy | $78 to $81 |
| 2014-11-11 | Boost Price Target | Williams Capital | Buy | $78.00 to $81.00 |
| 2014-11-04 | Reiterated Rating | Citigroup Inc. | Neutral | $71.00 to $74.00 |
| 2014-11-04 | Reiterated Rating | Credit Suisse | Neutral | $66.00 to $75.00 |
| 2014-11-04 | Reiterated Rating | Deutsche Bank | Buy | $74.00 to $80.00 |
| 2014-11-04 | Reiterated Rating | Jefferies Group | Buy | $75.00 to $82.00 |
| 2014-10-10 | Reiterated Rating | Bank of America | Underperform | $71.00 to $75.00 |
| 2014-10-09 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $74.00 |
| 2014-10-06 | Downgrade | Barclays | Equal Weight to Underweight | |
| 2014-08-04 | Reiterated Rating | Citigroup Inc. | Neutral | $73.00 to $71.00 |
| 2014-07-07 | Reiterated Rating | Jefferies Group | Buy | |
| 2014-05-02 | Reiterated Rating | Citigroup Inc. | Hold | $73.00 |
| 2014-05-02 | Boost Price Target | Oppenheimer | Outperform | $72.00 to $76.00 |
| 2014-05-02 | Boost Price Target | BMO Capital Markets | $71.00 to $74.00 | |
| 2014-04-11 | Reiterated Rating | Deutsche Bank | Buy | $70.00 to $74.00 |
| 2014-03-25 | Boost Price Target | Jefferies Group | $74.00 to $75.00 | |
| 2014-03-12 | Downgrade | Credit Suisse | Outperform to Neutral | $63.00 to $66.00 |
| 2014-02-05 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $65.00 to $71.00 |
| 2013-12-16 | Initiated Coverage | KeyBanc | Hold | |
| 2013-11-25 | Initiated Coverage | RBC Capital | Outperform to Sector Perform | $71.00 |
| 2013-11-25 | Initiated Coverage | Goldman Sachs | Buy | |
| 2013-11-04 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $68.00 to $71.00 |
| 2013-11-04 | Boost Price Target | Deutsche Bank | Buy | $66.00 to $70.00 |
| 2013-11-04 | Reiterated Rating | BMO Capital Markets | Hold | $62.00 |
| 2013-11-04 | Boost Price Target | Jefferies Group | Buy | $72.00 to $75.00 |
| 2013-09-23 | Initiated Coverage | Jefferies Group | Buy to Buy | $72.00 |
| 2013-09-17 | Upgrade | Deutsche Bank | Hold to Buy | $64.00 to $66.00 |
| 2013-08-08 | Reiterated | Williams Capital Group | Outperform | $70 to $79 |
| 2013-02-21 | Reiterated | Williams Capital Group | Outperform | $62 to $70 |
| 2012-12-21 | Initiated | William Blair | Outperform | |
| 2011-08-15 | Reiterated | William Blair | Outperform | $42.50 to $45.50 |
| 2010-11-10 | Reiterated | Deutsche Bank | Hold | $65 to $67 |
| 2016-07-11 | Initiated Coverage | Stifel Nicolaus | Hold | |
| 2016-05-22 | Reiterated Rating | Deutsche Bank | Buy | |
| 2016-05-22 | Reiterated Rating | Deutsche Bank AG | Buy | |
| 2016-05-20 | Reiterated Rating | Goldman Sachs | Sell | $81.00 |
| 2016-05-20 | Reiterated Rating | Goldman Sachs Group Inc. | Sell | $81.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CHD 622 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 29.03M |
| BlackRock Inc. | 19.56M |
| STATE STREET CORP | 12.21M |
| Fundsmith LLP | 8.46M |
| BlackRock Institutional Trust Company, N.A. | 7.53M |
| BlackRock Fund Advisors | 6.87M |
| GEODE CAPITAL MANAGEMENT, LLC | 5.06M |
| STIFEL FINANCIAL CORP | 3.78M |
| Invesco Ltd. | 3.70M |
| Neuberger Berman Group LLC | 3.35M |
| NORTHERN TRUST CORP | 2.86M |
| OPPENHEIMER FUNDS INC | 2.83M |
| BlackRock Group LTD | 2.80M |
| Capital International Investors | 2.58M |
| MORGAN STANLEY | 2.50M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| DIXON ROSINA B | 0.08% (106783) | CBM / CHD / |
| FARRELL MATTHEW Executive VP Finance and CFO | 0.08% (103684) | CHD / LDL / |
| Tursi Louis Executive VP, Consumer Sales | 0.05% (62237) | CHD / |
| WINKLEBLACK ARTHUR B | 0.04% (58469) | CHD / RTI / WEN / |
| Saligram Ravichandra Krishnamurty | 0.04% (56520) | ARMK / CHD / ODP / RBA / |
| FLEMING BRUCE F Executive V.P., CMO | 0.04% (55392) | CHD / |
| LEBLANC ROBERT D | 0.04% (48023) | CHD / |
| IRWIN BRADLEY C | 0.03% (43691) | CHD / |
| Craigie James Chairman and CEO | 0.02% (28116) | BLMN / CHD / MDP / SZYM / |
| Price Penry W | 0.01% (15773) | CHD / |
| SHEARER ROBERT K | 0.01% (14554) | CHD / TFM / VFC / |
| BROVA JACQUELIN J Executive V.P. Human Resources | 0.01% (12534) | CHD / |
| CONISH MARK G Executive VP Global Operations | 0.01% (11792) | CHD / |
| DE MAYNADIER PATRICK D EVP, Gen. Counsel & Secretary | 0.01% (9896) | CHD / |
| Siracusa Paul A Executive V.P., Global R&D | 0.01% (9760) | CHD / |
| Vergis Janet S. | 0.01% (8265) | CHD / IPXL / |
UM